Ocular Therapeutix faces looming test of a more durable eye treatment

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Welcome back, everyone! I missed you all. I spent a good bit of my holiday building the Lego version of the U.S.S. Enterprise: 3,600 pieces. I hope you found time to do something equally cool. 

Housekeeping note: I am flying out to San Francisco tomorrow for “JPM Week.” On Sunday, I’ll be sending an extra newsletter with my pre-conference thoughts. Look for that in your inbox.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In